BSEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioStem Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.54−0.55 (-26.32%)
Close on Oct 19, 2026
- Market cap
- $26.68M
- P/E (TTM)
- –
- Dividend yield
- –
BioStem Technologies statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | BioStem Technologies | Industry median |
|---|---|---|
| Market Cap | $27.49M | $166.30M |
| Enterprise Value | $20.53M | $88.19M |
| PB Ratio | 1.00 | 2.03 |
| P/TBV Ratio | 5.82 | 2.29 |
Balance sheet
| Measure | BioStem Technologies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.96M | $61.43M |
| Net Cash (Debt) | $6.96M | $15.35M |
| Net Cash Per Share | $0.39 | $0.66 |
| Equity (Book Value) | $27.61M | $49.09M |
| Book Value Per Share | $1.55 | $1.37 |
| Tangible Book Value | $4.72M | $23.52M |
| Working Capital | -$421.29K | $76.81M |
Financial position
| Measure | BioStem Technologies | Industry median |
|---|---|---|
| Current Ratio | 0.98 | 3.34 |
| Quick Ratio | 0.64 | 2.44 |
Shares
| Measure | BioStem Technologies | Industry median |
|---|---|---|
| Shares Outstanding | 17,849,500 | 58,127,000 |
| Float | 14,806,100 | 49,136,700 |
| Shares Held by Insiders | 17.1% | 11.6% |
Scores
| Measure | BioStem Technologies | Industry median |
|---|---|---|
| Altman Z-Score | -0.35 | -0.22 |
Calculated by StockData from BioStem Technologies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.